October 30, 2001

FOR: ZOLL Medical Corporation

INVESTOR CONTACT: A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655

PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832
rminicucci@zoll.com

FOR IMMEDIATE RELEASE

ZOLL Medical Corporation Announces

BURLINGTON, MA Tuesday, October 30, 2001 – ZOLL Medical Corporation (Nasdaq: ZOLL), a manufacturer of non-invasive cardiac resuscitation devices which provide pacing and defibrillation, today announced the release of the M Series CCT defibrillator. Designed specifically for patient transport, the CCT represents a significant extension of the highly successful M Series platform.

Adding a larger display and an extended life, the M Series CCT is the first defibrillator optimized for the transport of critical care patients. At just over 14 pounds, it is up to 21 percent lighter and 52 percent more compact than competitive offers. The standard output maximizes the device utility by allowing it to be easily connected to standard VGA displays. The CCT has options for transcutaneous pacing, capnography, 12 lead ECG, invasive and noninvasive blood pressure, and temperature.

Transport of critically ill patients presently requires healthcare providers to move with two pieces of equipment. Defibrillators are required as this population has a substantially higher risk of cardiac arrest. Transport monitors provide vital information on the evolution of a patient’s condition. The M Series CCT puts the functionality in one easy to use device.

Richard A. Packer, President and Chief Executive Officer of ZOLL commented, “The M Series CCT was designed to meet a long standing need in the market. Its all-in-one design eliminates the need for healthcare professionals to gather and carry two separate pieces of equipment. The CCT gives ZOLL a significant competitive advantage in the critical transport market.”

Mr. Packer added, “Launch of the M Series CCT marks another important milestone. It represents ZOLL’s first biphasic-only product. Given the current rate of acceptance for ZOLL’s Rectilinear Biphasic waveform, we simply felt efforts to bring out a monophasic version would be hard pressed to show a return.”

ZOLL completed introduction of the M Series CCT to its global sales team during the last several days. It is expected to make its formal market debut during next month’s annual meeting of the American Heart Association. The device has received FDA clearance. Shipments to both hospital and EMS markets are expected to begin during December.

ZOLL Medical Corporation designs, manufactures and markets an integrated line of proprietary non-invasive resuscitation devices and disposable electrodes. Used by healthcare professionals to provide both types of cardiac resuscitation – pacing and defibrillation – these products are essential in the emergency treatment of cardiac arrest victims both inside and outside the hospital. ZOLL also designs and markets software, which automates collection and management of both clinical and non-clinical data for emergency medical services.

Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, the intent, belief or current expectations of the Company, its directors or its officers, primarily with respect to the Company's business model and future operating performance of the Company, including expectations regarding results in future periods, operating performance, contributions to results from the Company’s new Public Access Defibrillation product, its ability to establish a new sales force in foreign markets, its expectations regarding future purchasing activity, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed on August 15, 2001, as well as uncertainties regarding the market, acceptance and profitability of the Company's new products and the desire or ability of other parties to purchase the Company's products.

###

News Room Resources

October 30, 2001

Related Info